Abstract:Introduction: The biomedical industry has grown significantly both globally and in China; however, there are still challenges. This study aimed at evaluating the biopharmaceutical sector of China, in terms of ability to innovate, current sales volume, investment, and R&D expenditure, as well as providing a case study detailing the progress and challenges of the industry in Shaanxi province. Method: A cross-sectional mixed-method study design was used to generate a comprehensive profile of the nature of biopharmaceutical innovation capacity and development in China by triangulating country-wide survey and interview data from Shaanxi province. Only biopharmaceutical companies that are currently marketing or conducting research and development were eligible for inclusion, and Shaanxi province was selected for conducting the interviews. Categorical and continuous variables were analyzed descriptively. Interviews were thematically analyzed by using NVivo version 12. Results: The analysis includes responses from 77 biopharmaceutical enterprises; the majority (36, 46.8%) are in Eastern China, followed by 26 (33.8%) in Central China. In 2018, the total sales of biological products amounted to 26.28 billion yuan, and in 2019, a slight increase was observed (30.34 billion); the amount doubled in 2020 to about 67.91 billion yuan. The top three biopharmaceutical products on sale in 2020 were Camrelizumab (5.14 billion yuan), human albumin (4.56 billion yuan), and human immunoglobulin for injection (3.78 billion yuan). Expenditure on R&D has also increased; it amounted to 1657.7 million yuan in 2018, which more than doubled in 2019 to 3572.1 million yuan and further increased to 5857.7 million yuan in 2020. Nonetheless, the progress is not uniform across all provinces, as shown from the results from Shaanxi province, because of lack of local government policies that will impact on the funding, incentives, and market share that motivate the producers. Conclusion: China's biopharmaceutical industry has expand significantly. The increase in sales indicates that there is an increase in demand for biologicals; moreover, R&D funding is increasing. These are key indicators that influence innovation and development. However, the sector's capacity to innovate and develop needs to be improved, particularly in the western region, where research and production are relatively weak.

A Financial Analysis and Valuation of Livzon Group

Analysis of Investment Value in the Traditional Chinese Medicine Industry: A Case Study of Yiling Pharmaceutical Co., Ltd.

Development Environment and SWOT Analysis of Biomedical SMEs after COVID-19: Evidence from China

A Financial Analysis and Valuation of Elevance Health, Inc.

A Valuation Model for the Development of Sinovac Biological Company under COVID-19 Shock

Behavior and Consequences of COVID-19-related Voluntary Disclosure: Evidence from Pharmaceutical Companies

Prediction of the financial risk of Special Treatment of a Listed Pharmaceutical Company in China: A Principal Component Analysis (Preprint)

Risks Analysis and Development Prediction in Pharmaceutical Industry: A Case Study of Johnson and Johnson, Pfizer and Roche

Financial Risk Analysis of the Pharmaceutical Industry Based on Z-score Model: A Case Study of Changjiang Health

Representative Stock Analysis in Chinese Medical Industry and Relevant Investment Recommendations

Financial Analysis of the Pharmaceutical Industry Based on Dupont Analysis: Taking Guangzhou Baiyunshan Pharmaceutical Group as an Example

Fundamental Stock Analysis in COVID-19 Vaccines Industry

Research on the Risk Management of Pharmaceutical Circulation Enterprises -- Taking Sinopharm Holding Co., Ltd as an Example Based on Data Analysis

Current situation and future development of the biopharmaceutical industry in China: A mixed-method study

Research on the Motivation and Performance of China Resources Pharmaceutical M&A

Product Line Transformation, Foreign Sales, and Firm Value: Evidence from COVID-19 Pandemic Governance in Urban China

Do Investors Repeat History: Evidence from Post-pandemic Pharmaceuticals Industry

Case Study of Financial Situation Based on Harvard Analysis Framework

An Analysis of the Influence of Chinese Enterprises' Transnational Leveraged Buyouts

Corporate Financial Measures and Covid-19 Pandemic with Evidence from the Growth Enterprise Market of China’s Shenzhen Stock Exchange

Research on the Current Situation and Countermeasures of Inventory Management of Xin Zhongkang Pharmaceutical Company